SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alliance Pharmaceutical
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: 993racer who wrote (298)8/12/1998 4:20:00 PM
From: All Mtn Ski  Read Replies (1) of 548
 
Northfield news:

NORTHFIELD LABORATORIES INC. said the FDA asked the company to increase the number of patients included in the Phase III clinical trials of its blood substitute, PolyHeme, which will delay completion of the trials. Northfield said the FDA based its request on what it called public concern over failures of competing products in Phase III trials. The company said its Phase III trials so far have not shown negative results. At the same time, Northfield said the FDA cleared Northfield to infuse up to 20 units of PolyHeme, essentially double the blood volume of the average adult, in continuing Phase II trials being conducted with trauma patients. (Reuters 09:55 AM ET 08/12/98) For the full text story, see infobeat.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News